FDA says Pepaxto, Copiktra may cause higher risk of death, but EMA has recently endorsed both

Minerva nears make-or-break readouts from its two founding neuropsychiatry programs

For tissue-agnostic drug development to go big, NGS needs to become routine with community oncologists

How patient prevalence and market access could encourage companies to launch their drugs first in China.

How 2019 milestones could see Aslan benefit from its 2012 strategy shift